{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010481","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.073304+00:00","generated_at":"2026-06-14T14:57:00.302536+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xilio reports encouraging Phase 1 data for XTX101: partial response in PD-L1 neg NSCLC, favorable safety at RP2D","bullets":["Preliminary data from Phase 1 trial of XTX101 in 25 patients with advanced solid tumors; RP2D set at 150 mg Q6W.","Partial response observed at nine weeks in a PD-L1 negative advanced NSCLC patient with hepatic metastases, continuing on treatment.","At RP2D, no Grade 4/5 treatment-related AEs, no colitis or infusion reactions; only Grade 3 AE was diarrhea (resolved).","Evidence of tumor-selective activation: low unmasked drug in peripheral circulation and minimal immune activation in periphery.","Plans to explore XTX101 in combination with PD-(L)1 in immunotherapy-resistant tumor types, including MSI-stable CRC."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010481","json":"https://secwatch.observer/filing/0001558370-23-010481.json","markdown":"https://secwatch.observer/filing/0001558370-23-010481.md","text":"https://secwatch.observer/filing/0001558370-23-010481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023010481/0001558370-23-010481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023010481/xlo-20230525x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:57:00.302536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}